Request a call

jrk-logo
  •  +91 8925186164
     +91 8667653268
  •  +91-44-7125 5000 / 6625 5777 / 4958 3968
banner

CTRI registered clinical trial (Reference no. CTRI/2014/10/005143)


Clinical trial was done on 30 Psoriasis patients with various extents of Psoriatic lesions for a period of 12 weeks.

Study Findings

  • 1-3-2 topical treatment with Dr.JRK’s 777 oil, Psorolin medicated bathing bar, Psorolin oil and Psorolin ointment showed significant improvement even when the extent of lesions in the body was 75% or more.
  • Significant improvement (87.61%) in PASI (Psoriasis area severity index) score was recorded which proves the efficacy of 1-3-2 treatment approach.

Improvement in PASI score

Extent of lesions

Monotherapy with Dr.JRK's 777 oil, Monotherapy with Psorolin ointment, Combination therapy - Dr.JRK's 777 oil + Psorolin ointment



CTRI registered clinical trial (Reference no. CTRI/2014/01/004277)


CTRI registered clinical study was done on 42 patients for 12 weeks with Dr.JRK’s 777 oil and Psorolin ointment

Study Findings

  • Combination therapy with Dr. JRK’s 777 oil and Psorolin ointment had greater reduction of mean PGA score during study period when compared to monotherapy with Dr. JRK’s 777 oil or Psorolin ointment.

combination therapy had greater reduction of mean PGA score in the study period

Day 1

12 Weeks

Monotherapy with Dr.JRK's 777 oil, Monotherapy with Psorolin ointment, Combination therapy - Dr.JRK's 777 oil + Psorolin ointment

1 - Dr.JRK's 777 oil Mono therapy

2 - Psorolin ointment monotherapy

3 - combination therapy



  • 1-3-2 treatment with reference to the circadian rhythm provides greater success in management of Psoriasis.
  • Keratinocyte proliferation and elastase enzyme activity worsen Psoriasis.
  • Skin cell proliferation is more during late night to early morning hours whereas enzyme activity remains high during daytime and early night hours.
  • Psorolin oil and Psorolin ointment possess specific role in inhibition of these symptoms and are proven to be non-cytotoxic nature.

Both Psorolin oil and Psorolin ointment are essential for the treatment of Psoriasis


Study 1: Psorolin oil effectively inhibits keratinocyte proliferation


Cell proliferation assay - MTT assay:

Concentrations (µg/ml) % Inhibition of neonatal keratinocytes (Skin cells)
300 400 500
Psorolin oil 41.51 49.31 63.71
Psorolin ointment 2.35 4.19 35.82

Note: Control group – Showed nil inhibition

Study Findings

  • Percentage of keratinocyte proliferation inhibition was more in Psorolin oil treated cells than that in Psorolin ointment treated cells.

Study 2: Psorolin ointment effectively inhibits elastase enzyme activity.


Elastase inhibition assay:

  • Increased level of elastase enzyme worsen the Psoriasis condition and affects the elasticity of the skin.
  • Elastase enzyme is generated more in Psoriasis conditions.
Concentrations (µg/ml) % Inhibition Elastase
300 400
Psorolin oil 5.19 12.17
Psorolin ointment 21.52 41.62

Note: Control group – Showed nil inhibition

Study Findings

  • Percentage inhibition of elastase enzyme activity was more in Psorolin ointment treated cells than that in Psorolin oil treated cells.

Psorolin Oil and Psorolin Ointment proven to be non-cytotoxic

Both the products (i.e) Psorolin Oil and Psorolin Ointment are tested by Tryphan blue assay and LDH assay to reconfirm their non-cytotoxic nature


Study Findings


  • Both Typhan blue exclusion and LDH assay showed no damage to the treated cells has occurred even at higher dosage of the products.